CBO discusses prescription drug prices and approaches aimed at reducing those prices. Some of the approaches would cap prices or limit their growth, and other approaches would promote price competition or affect the flow of information.
Reducing drug prices would save money for patients and payers, but reducing manufacturers’ expected revenue from drugs that are not yet on the market would make investments in pharmaceutical research and development less profitable, thus decreasing the number of new drugs developed and introduced. Larger reductions in expected revenue would have a greater effect than smaller reductions.
Same propaganda we’ve been fed for decades. You gotta let the companies screw you over or else.
Same propaganda we’ve been fed for decades. You gotta let the companies screw you over or else.